Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantBC
Breyer Capital
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Sep 18, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $135M 1 disclosed · full round size, not this investor’s share